Exact Mass: 362.1954

Exact Mass Matches: 362.1954

Found 104 metabolites which its exact mass value is equals to given mass value 362.1954, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

17,21-Epoxy-9-fluoro-11beta-hydroxyprogesterone

17,21-Epoxy-9-fluoro-11-hydroxypregn-4-ene-3,20-dione, (11beta)-

C21H27FO4 (362.1893)


   

N-(4-Fluorophenyl)-4,5-dimethyl-6-[(1S)-1-methyl-3,4-dihydro-1H-isoquinolin-2-YL]pyrimidin-2-amine

N-(4-Fluorophenyl)-4,5-dimethyl-6-[(1S)-1-methyl-3,4-dihydro-1H-isoquinolin-2-YL]pyrimidin-2-amine

C22H23FN4 (362.1907)


C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent

   

Benzetimide

3-(1-benzylpiperidin-4-yl)-6-hydroxy-3-phenyl-2,3,4,5-tetrahydropyridin-2-one

C23H26N2O2 (362.1994)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

   

Aikupikanyne F

Aikupikanyne F

C24H26O3 (362.1882)


   

Machaeridiol C

Machaeridiol C

C24H26O3 (362.1882)


   

Machaeriol B

Machaeriol B

C24H26O3 (362.1882)


   
   

9R-(beta-D-glucopyranosyloxy)-cis-cascarillic acid|parisveroside A

9R-(beta-D-glucopyranosyloxy)-cis-cascarillic acid|parisveroside A

C17H30O8 (362.1941)


   

phenaziterpene B

phenaziterpene B

C23H26N2O2 (362.1994)


   

jasminoid C

jasminoid C

C17H30O8 (362.1941)


   

serylthreonylarginine

serylthreonylarginine

C13H26N6O6 (362.1914)


   

threonylserylarginine

threonylserylarginine

C13H26N6O6 (362.1914)


   
   

isoleucylcysteyllysine

isoleucylcysteyllysine

C15H30N4O4S (362.1988)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(±)-JWH 018 N-(4-hydroxypentyl) metabolite-d5

(±)-JWH 018 N-(4-hydroxypentyl) metabolite-d5

C24H18D5NO2 (362.2043)


   

JWH 018 N-(5-hydroxypentyl) metabolite-d5

JWH 018 N-(5-hydroxypentyl) metabolite-d5

C24H18D5NO2 (362.2043)


   

Bufogargarizin C

Bufogargarizin C

C24H26O3 (362.1882)


   
   

(4R,4R)-2,2-(PROPANE-2,2-DIYL)BIS(4-BENZYL-4,5-DIHYDROOXAZOLE)

(4R,4R)-2,2-(PROPANE-2,2-DIYL)BIS(4-BENZYL-4,5-DIHYDROOXAZOLE)

C23H26N2O2 (362.1994)


   

solifenacin

solifenacin

C23H26N2O2 (362.1994)


G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents Solifenacin (YM905 free base) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.

   

1,3-Bis(glycidoxypropyl)tetramethyldisiloxane

1,3-Bis(glycidoxypropyl)tetramethyldisiloxane

C16H34O5Si2 (362.1945)


   

N-(2-((tert-Butyldimethylsilyloxy)methyl)furo[3,2-b]pyridin-7-yl)pivalamide

N-(2-((tert-Butyldimethylsilyloxy)methyl)furo[3,2-b]pyridin-7-yl)pivalamide

C19H30N2O3Si (362.2026)


   

sodium n-tridecylbenzenesulfonate

sodium n-tridecylbenzenesulfonate

C19H31NaO3S (362.1891)


   

4,4-DIISOCYANATO-3,3,5,5-TETRAETHYLDIPHENYLMETHANE

4,4-DIISOCYANATO-3,3,5,5-TETRAETHYLDIPHENYLMETHANE

C23H26N2O2 (362.1994)


   

Dexetimide

benzetimide

C23H26N2O2 (362.1994)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists Dexetimide ((+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide) is a piperidine anticholinergic and a high-affinity muscarinic receptor antagonist. Dexetimide can be used in studies of parkinson's disease[1][2].

   

EPOXYPROPOXYPROPYL TERMINATED POLYDIMETHYLSILOXANE

EPOXYPROPOXYPROPYL TERMINATED POLYDIMETHYLSILOXANE

C16H34O5Si2 (362.1945)


   

4-(4-propylcyclohexyl)-4-(trifluoromethoxy)-1,1-biphenyl

4-(4-propylcyclohexyl)-4-(trifluoromethoxy)-1,1-biphenyl

C22H25F3O (362.1857)


   

2,8-Diazaspiro[5.5]undecane-1,7-dione, 2,8-bis(phenylmethyl)-

2,8-Diazaspiro[5.5]undecane-1,7-dione, 2,8-bis(phenylmethyl)-

C23H26N2O2 (362.1994)


   

1-[4-[1-(3-methoxy-4-nitrophenyl)piperidin-4-yl]piperazin-1-yl]ethanone

1-[4-[1-(3-methoxy-4-nitrophenyl)piperidin-4-yl]piperazin-1-yl]ethanone

C18H26N4O4 (362.1954)


   

4-[3-Oxo-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-YL)-propenyl]-benzoic acid

4-[3-Oxo-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-YL)-propenyl]-benzoic acid

C24H26O3 (362.1882)


   

Clometherone

Clometherone

C22H31ClO2 (362.2012)


C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist

   

1,1,4,4-Tetraphenylbutane

1,1,4,4-Tetraphenylbutane

C28H26 (362.2034)


   

(6S)-6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one

(6S)-6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one

C21H27FO4 (362.1893)


   

(3r)-3-Hydroxy-2,2-Dimethyl-4-Oxo-4-({3-Oxo-3-[(2-Sulfanylethyl)amino]propyl}amino)butyl 2,2-Dimethylpropanoate

(3r)-3-Hydroxy-2,2-Dimethyl-4-Oxo-4-({3-Oxo-3-[(2-Sulfanylethyl)amino]propyl}amino)butyl 2,2-Dimethylpropanoate

C16H30N2O5S (362.1875)


   

benzetimide

benzetimide

C23H26N2O2 (362.1994)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

   

5-(Phenylmethoxymethyl)-7-(1-piperidinylmethyl)-8-quinolinol

5-(Phenylmethoxymethyl)-7-(1-piperidinylmethyl)-8-quinolinol

C23H26N2O2 (362.1994)


   

(4S)-4-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [(3R)-1-azabicyclo[2.2.2]octan-3-yl] ester

(4S)-4-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [(3R)-1-azabicyclo[2.2.2]octan-3-yl] ester

C23H26N2O2 (362.1994)


   

17,21-Epoxy-9-fluoro-11-hydroxypregn-4-ene-3,20-dione, (11beta)-

17,21-Epoxy-9-fluoro-11-hydroxypregn-4-ene-3,20-dione, (11beta)-

C21H27FO4 (362.1893)


   

N(6)-L-homocysteinyl-N(2)-L-valyl-L-lysine

N(6)-L-homocysteinyl-N(2)-L-valyl-L-lysine

C15H30N4O4S (362.1988)


   
   
   
   

1-[(4-Chlorophenyl)-[1-(2-methylbutan-2-yl)-5-tetrazolyl]methyl]-4-methylpiperazine

1-[(4-Chlorophenyl)-[1-(2-methylbutan-2-yl)-5-tetrazolyl]methyl]-4-methylpiperazine

C18H27ClN6 (362.1986)


   

N-[2-[(2R,5S,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

N-[2-[(2R,5S,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

C18H26N4O4 (362.1954)


   

N-[2-[(2R,5R,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

N-[2-[(2R,5R,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

C18H26N4O4 (362.1954)


   

N-[2-[(2S,5S,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

N-[2-[(2S,5S,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

C18H26N4O4 (362.1954)


   

1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

C23H26N2O2 (362.1994)


   

(6S,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6S,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H26N2O2 (362.1994)


   

N-[2-[(2S,5R,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

N-[2-[(2S,5R,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

C18H26N4O4 (362.1954)


   

N-[2-[(2R,5R,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

N-[2-[(2R,5R,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

C18H26N4O4 (362.1954)


   

N-[2-[(2R,5S,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

N-[2-[(2R,5S,6S)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

C18H26N4O4 (362.1954)


   

N-[2-[(2S,5S,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

N-[2-[(2S,5S,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

C18H26N4O4 (362.1954)


   

N-[2-[(2S,5R,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

N-[2-[(2S,5R,6R)-5-[[cyclobutyl(oxo)methyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-pyrazinecarboxamide

C18H26N4O4 (362.1954)


   

1-[(3aS,4R,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

1-[(3aS,4R,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

C23H26N2O2 (362.1994)


   

1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

C23H26N2O2 (362.1994)


   

1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

C23H26N2O2 (362.1994)


   

(6R,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6R,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H26N2O2 (362.1994)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

revaprazan

revaprazan

C22H23FN4 (362.1907)


C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent

   

Levetimide

Levetimide

C23H26N2O2 (362.1994)


Levetimide is a potent and stereoselective inhibitor of [3H](+)pentazocine binding, with a Ki of 2.2 nM[1].

   

(2E,6E)- 3,7,11-trimethyl-9-(phenylsulfonyl)-2,6,10-dodecatrien-1-ol

NA

C21H30O3S (362.1916)


{"Ingredient_id": "HBIN005569","Ingredient_name": "(2E,6E)- 3,7,11-trimethyl-9-(phenylsulfonyl)-2,6,10-dodecatrien-1-ol","Alias": "NA","Ingredient_formula": "C21H30O3S","Ingredient_Smile": "CC(=CC(CC(=CCCC(=CCO)C)C)S(=O)(=O)C1=CC=CC=C1)C","Ingredient_weight": "362.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "41632","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "5368759","DrugBank_id": "NA"}

   

5-(1-benzofuran-2-yl)-2-[(1s,2s,5s)-5-methyl-2-(prop-1-en-2-yl)cyclohexyl]benzene-1,3-diol

5-(1-benzofuran-2-yl)-2-[(1s,2s,5s)-5-methyl-2-(prop-1-en-2-yl)cyclohexyl]benzene-1,3-diol

C24H26O3 (362.1882)


   

23-oxotetracosa-3,5,7,9,11,13,15,17,19,21-decaenoic acid

23-oxotetracosa-3,5,7,9,11,13,15,17,19,21-decaenoic acid

C24H26O3 (362.1882)


   

(2r,21z)-2-hydroxytetracos-21-en-3,12,14,16,23-pentaynoic acid

(2r,21z)-2-hydroxytetracos-21-en-3,12,14,16,23-pentaynoic acid

C24H26O3 (362.1882)


   

1-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-6-methoxyphenazine

1-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-6-methoxyphenazine

C23H26N2O2 (362.1994)


   

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 9-hydroxy-3-methyldec-2-enoate

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 9-hydroxy-3-methyldec-2-enoate

C17H30O8 (362.1941)


   

(3e,5e,7e,9e,11e,13e,15e,17e,19e,21e)-23-oxotetracosa-3,5,7,9,11,13,15,17,19,21-decaenoic acid

(3e,5e,7e,9e,11e,13e,15e,17e,19e,21e)-23-oxotetracosa-3,5,7,9,11,13,15,17,19,21-decaenoic acid

C24H26O3 (362.1882)


   

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2z)-9-hydroxy-3-methyldec-2-enoate

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2z)-9-hydroxy-3-methyldec-2-enoate

C17H30O8 (362.1941)


   

(6as,9s,10as)-3-(1-benzofuran-2-yl)-6,6,9-trimethyl-6ah,7h,8h,9h,10h,10ah-benzo[c]isochromen-1-ol

(6as,9s,10as)-3-(1-benzofuran-2-yl)-6,6,9-trimethyl-6ah,7h,8h,9h,10h,10ah-benzo[c]isochromen-1-ol

C24H26O3 (362.1882)


   

1-{[(2e)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-6-methoxyphenazine

1-{[(2e)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-6-methoxyphenazine

C23H26N2O2 (362.1994)